How to Identify Early Buprenorphine Nonresponse in the First 2 Weeks
How should clinicians use opioid use reported in the first 2 weeks of buprenorphine treatment to identify patients at risk for poor short-term outcomes?
Many patients starting buprenorphine continue some opioid use early in treatment, and clinicians need a practical way to decide when that use signals elevated risk rather than expected early instability. This guide applies to patients with opioid use disorder receiving buprenorphine when weekly early follow-up is available and self-reported opioid use can be reviewed.
-
Track opioid use during weeks 1 and 2
Ask the patient to report the number of days of illicit opioid use across the first 14 treatment days. The study derived its threshold from self-reported daily opioid use frequency collected with a calendar-based method and analyzed this at the weekly level to reflect routine clinical practice.
-
Classify any use as early nonresponse
Treat 1 or more days of opioid use during weeks 1 to 2 as the early nonresponse threshold. In this analysis, the optimal cutoff for weeks 1 to 2 was 1 day or more of use out of 14 days.
-
Interpret the threshold as a broad risk screen
Use this cutoff when the clinical goal is to capture a broader at-risk group early. The weeks 1 to 2 threshold had sensitivity 0.747 and specificity 0.688, indicating it was better suited to reducing false negatives than to narrowly identifying only the highest-risk patients.
-
Estimate the patient’s near-term risk
Recognize that early nonresponse by this definition was associated with 6.43 times greater odds of sustained opioid use during weeks 5 to 12. Descriptively, 52% of patients with any opioid use in the first 2 weeks later reported sustained use, compared with 14% of those abstinent during this period.
-
Use the result to intensify observation and adjust treatment
If the patient meets the threshold, increase clinical attention because early nonresponse was also associated with about 3.12 fewer opioid-free weeks and 1.11 fewer weeks retained in treatment. The authors state that patients above this threshold may need close observation and treatment adjustments such as increased buprenorphine dose, switching formulations, adjunctive behavioral treatment, harm-reduction counseling, or targeted efforts to improve retention.
Clinical Considerations
- This threshold was derived from clinical trial data collected before synthetic fentanyl dominated the drug supply, so the cutoff may differ in patients primarily using fentanyl.
- The sample was largely non-Hispanic and white, which limits certainty about generalizability to more racially diverse populations.
- The weeks 1 to 2 threshold had better negative predictive value than positive predictive value, so it is more useful for ruling out later sustained use than for definitively identifying who will do poorly.
- One included trial contributed phase 2 participants who had already returned to opioid use after an earlier taper, which may affect how broadly the findings apply.
Bottom Line
Any illicit opioid use in the first 2 weeks of buprenorphine treatment should be treated as an early warning sign that warrants closer monitoring and treatment adjustment.
